Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
Similar Companies1000
NovImmune
NovImmune is a biopharmaceutical company that develops therapeutic monoclonal antibodies to treat immune-related disorders.
Sector
Subsector
Keywords
Location
total rounds
total raised
Vaccinex
Vaccinex develops targeted biotherapeutics for cancer, neurodegenerative diseases, and autoimmune disorders.
Sector
Subsector
Keywords
Location
total rounds
total raised
Kanaph Therapeutics
Kanaph Therapeutics is a biotech company that develops next-generation therapeutics for oncology and autoimmune diseases.
Sector
Subsector
Location
total rounds
total raised
AltruBio
AltruBio is a biopharmaceutical company developing targeted antibody therapeutics for cancer and immune-related inflammatory diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds6
Co-Investors
People
Founders2
Richard Klemke, PhD.
Dr. Klemke has over 25 years of experience working in academia and the biotechnology sectors in the San Diego area. Dr. Klemke is Professor of Pathology and Cancer Biology at the University of California San Diego School of Medicine and Moores Cancer Center, where he serves as the director of the Cancer Imaging Network and the Pathology Department’s Proteomics Center of Excellence. He earned his Ph.D. in Molecular Cell Biology from Texas Tech University Health Sciences Center. Dr. Klemke was a research scientist in the immunology department at The Scripps Research Institute (TSRI) before joining UC San Diego and Moores in 2006. He has been an active consultant in the biotech and pharmaceutical industries for more than two decades, and is the founder of BioSystems Consulting in San Diego. He is internationally recognized for his work in stem cell biology, carcinogenesis, and therapeutic drug development, using proteomics, computational biology, and unique cell-based and preclinical animal models of cancer. His work has produced novel therapeutics directed at cancer and has unlocked newfound insights and concepts that explain how malignant tumors develop and avoid the immune system to spread through the body.
current job
organization founded
Richard Klemke, PhD.
Remo Moomiaie-Qajar M.D.
Dr. Moomiaie-Qajar is a trained surgeon from Yale University with a long academic history of innovating technologies in medicine and translating them into commercially viable products. Dr. Moomiaie-Qajar has 15 years of experience incubating technologies from start-up or early stage level to exit. His background as an academic researcher, physician, and entrepreneur brings an unique trifecta of perspective and experience to Cytonus. He holds a number of US and International Patents and has successfully funded and launched a number of Life Science companies. He is the past CEO of Remo CRO, a full service CRO and Dr. Moomiaie-Qajar is an active member of a number of National Angel Investment Groups and manages a Life Science seed fund.
current job
Remo Moomiaie-Qajar M.D.